Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410
Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that dosing is complete in the first cohort of its Phase 1/2 ArMaDa clinical…
Memorial Sloan Kettering Cancer Center Now Enrolling Patients in Phase 1/2 Clinical Trial of IMUNON’s IMNN-001 in Combination with Bevacizumab in Advanced Ovarian Cancer
IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces that Memorial Sloan Kettering Cancer Center has joined MD Anderson Cancer Center in enrolling patients in a Phase 1/2 clinical trial evaluating IMUNON’s IMNN-001 in…
Glenmark’s innovative immune-oncology drug for advanced solid tumors and lymphomas receives FDA acceptance for Phase 1/2 clinical study
Glenmark Pharmaceuticals Ltd.’s subsidiary, Glenmark Specialty SA, has achieved a breakthrough in the fight against advanced solid tumors and lymphomas. The US Food and Drug Administration (FDA) has accepted the company’s Investigational New Drug (IND) application for GRC 54276, an…
